Drugs / BNA035
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05150457 | Feb 2022 → Nov 2023 | refractory malignant neoplasm | Binacea Pharma, Inc. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BNA035 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05150457 ↗ |
| Route | Intravenous | “administered as an IV infusion” NCT05150457 ↗ |
| Target | EGFR | “Anti-epidermal growth factor receptor (Anti-EGFR)” NCT05150457 ↗ |